Page 1 | Search Results | Blood Advances | American Society of Hematology

1-20 of 38

Sort by

Sort Order Select

Journal Articles

Not all patients with AML over 60 years of age should be offered early allogeneic stem cell transplantation

H. Joachim Deeg

Blood Adv (2022) 6 (5): 1623–1627.

https://doi.org/10.1182/bloodadvances.2021004799

Published: 2022

Journal Articles

Better the cure you know: why patients with AML ≥60 years of age should be offered early allogeneic stem cell transplantation

Siok-Keen Tey, Steven W. Lane

Blood Adv (2022) 6 (5): 1619–1622.

https://doi.org/10.1182/bloodadvances.2021004829

Published: 2022

Journal Articles

Is a BTKi or BCL2i preferable for first “novel” therapy in CLL? The case for BTKis

Elizabeth A. Brem, Susan O’Brien

Blood Adv (2022) 6 (4): 1361–1364.

https://doi.org/10.1182/bloodadvances.2019001204

Published: 2022

Journal Articles

Is BTKi or BCL2i preferable as first novel therapy in patients with CLL? The case for BCL2i

John F. Seymour

Blood Adv (2022) 6 (4): 1365–1370.

https://doi.org/10.1182/bloodadvances.2019001205

Published: 2022

Journal Articles

BiTEs better than CAR T cells

Marion Subklewe

Blood Adv (2021) 5 (2): 607–612.

https://doi.org/10.1182/bloodadvances.2020001792

Published: 2021

Journal Articles

CAR T cells better than BiTEs

John C. Molina, Nirali N. Shah

Blood Adv (2021) 5 (2): 602–606.

https://doi.org/10.1182/bloodadvances.2020003554

Published: 2021

Journal Articles

Maintenance therapy for high-risk acute leukemia after allogeneic hematopoietic cell transplantation: wait a minute

Robert J. Soiffer

Blood Adv (2020) 4 (13): 3205–3208.

https://doi.org/10.1182/bloodadvances.2019000389

Published: 2020

Journal Articles

Allogeneic stem cell transplantation for high-risk acute leukemia and maintenance therapy: no time to waste

Bart L. Scott

Blood Adv (2020) 4 (13): 3200–3204.

https://doi.org/10.1182/bloodadvances.2019000388

Published: 2020

Journal Articles

Stem cell donors should be screened for CHIP

Amy E. DeZern, Lukasz P. Gondek

Blood Adv (2020) 4 (4): 784–788.

https://doi.org/10.1182/bloodadvances.2019000394

Published: 2020

Journal Articles

Stem cell donors should not be screened for clonal hematopoiesis

Christopher J. Gibson, R. Coleman Lindsley

Blood Adv (2020) 4 (4): 789–792.

https://doi.org/10.1182/bloodadvances.2019000395

Published: 2020

Journal Articles

Do next-generation sequencing results drive diagnostic and therapeutic decisions in MDS?

Guillermo F. Sanz, Mariam Ibañez, Esperanza Such

Blood Adv (2019) 3 (21): 3454–3460.

https://doi.org/10.1182/bloodadvances.2019000680

Published: 2019

Journal Articles

Do next-generation sequencing results drive diagnostic and therapeutic decisions in MDS?

Felicitas Thol, Uwe Platzbecker

Blood Adv (2019) 3 (21): 3449–3453.

https://doi.org/10.1182/bloodadvances.2018022434

Published: 2019

Journal Articles

Delay treatment of AL amyloidosis at relapse until symptomatic: devil is in the details

Vaishali Sanchorawala

Blood Adv (2019) 3 (2): 216–218.

https://doi.org/10.1182/bloodadvances.2018021261

Published: 2019

Journal Articles

When should treatment of AL amyloidosis start at relapse? Early, to prevent organ progression

Giovanni Palladini, Giampaolo Merlini

Blood Adv (2019) 3 (2): 212–215.

https://doi.org/10.1182/bloodadvances.2018021253

Published: 2019

Journal Articles

Imatinib is still recommended for frontline therapy for CML

Andrew Hantel, Richard A. Larson

Blood Adv (2018) 2 (24): 3648–3652.

https://doi.org/10.1182/bloodadvances.2018018614

Published: 2018

Journal Articles

A second-generation TKI should always be used as initial therapy for CML

Jorge E. Cortes

Blood Adv (2018) 2 (24): 3653–3655.

https://doi.org/10.1182/bloodadvances.2018018655

Published: 2018

Journal Articles

Timing of treatment of smoldering myeloma: early treatment

María-Victoria Mateos, Verónica González-Calle

Blood Adv (2018) 2 (21): 3045–3049.

https://doi.org/10.1182/bloodadvances.2018021220

Published: 2018

Journal Articles

Timing of treatment of smoldering myeloma: delay until progression

Shaji K. Kumar

Blood Adv (2018) 2 (21): 3050–3053.

https://doi.org/10.1182/bloodadvances.2018021238

Published: 2018

Journal Articles

Emicizumab should be prescribed independent of immune tolerance induction

Sandra Le Quellec, Claude Negrier

Blood Adv (2018) 2 (20): 2783–2786.

https://doi.org/10.1182/bloodadvances.2018015859

Published: 2018

Journal Articles

Implementing emicizumab in hemophilia inhibitor management: emicizumab should be prescribed after tolerance

Guy Young

Blood Adv (2018) 2 (20): 2780–2782.

https://doi.org/10.1182/bloodadvances.2018015842

Published: 2018

NARROW

Not all patients with AML over 60 years of age should be offered early allogeneic stem cell transplantation

Better the cure you know: why patients with AML ≥60 years of age should be offered early allogeneic stem cell transplantation

Is a BTKi or BCL2i preferable for first “novel” therapy in CLL? The case for BTKis

Is BTKi or BCL2i preferable as first novel therapy in patients with CLL? The case for BCL2i

BiTEs better than CAR T cells

CAR T cells better than BiTEs

Maintenance therapy for high-risk acute leukemia after allogeneic hematopoietic cell transplantation: wait a minute

Allogeneic stem cell transplantation for high-risk acute leukemia and maintenance therapy: no time to waste

Stem cell donors should be screened for CHIP

Stem cell donors should not be screened for clonal hematopoiesis

Do next-generation sequencing results drive diagnostic and therapeutic decisions in MDS?

Do next-generation sequencing results drive diagnostic and therapeutic decisions in MDS?

Delay treatment of AL amyloidosis at relapse until symptomatic: devil is in the details

When should treatment of AL amyloidosis start at relapse? Early, to prevent organ progression

Imatinib is still recommended for frontline therapy for CML

A second-generation TKI should always be used as initial therapy for CML

Timing of treatment of smoldering myeloma: early treatment

Timing of treatment of smoldering myeloma: delay until progression

Emicizumab should be prescribed independent of immune tolerance induction

Implementing emicizumab in hemophilia inhibitor management: emicizumab should be prescribed after tolerance

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only